These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

230 related articles for article (PubMed ID: 35721187)

  • 21. Elexacaftor/tezacaftor/ivacaftor and gastrointestinal outcomes in cystic fibrosis: Report of promise-GI.
    Schwarzenberg SJ; Vu PT; Skalland M; Hoffman LR; Pope C; Gelfond D; Narkewicz MR; Nichols DP; Heltshe SL; Donaldson SH; Frederick CA; Kelly A; Pittman JE; Ratjen F; Rosenfeld M; Sagel SD; Solomon GM; Stalvey MS; Clancy JP; Rowe SM; Freedman SD;
    J Cyst Fibros; 2023 Mar; 22(2):282-289. PubMed ID: 36280527
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Phase 1 Study to Assess the Safety and Pharmacokinetics of Elexacaftor/Tezacaftor/Ivacaftor in Subjects Without Cystic Fibrosis With Moderate Hepatic Impairment.
    Viswanathan L; Bachman E; Tian S; Ahluwalia N; Zhang Y; Bernstein HS; Panorchan P
    Eur J Drug Metab Pharmacokinet; 2022 Nov; 47(6):817-825. PubMed ID: 36036885
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Elexacaftor/Tezacaftor/Ivacaftor in Patients with Cystic Fibrosis Homozygous for the
    Carnovale V; Iacotucci P; Terlizzi V; Colangelo C; Ferrillo L; Pepe A; Francalanci M; Taccetti G; Buonaurio S; Celardo A; Salvadori L; Marsicovetere G; D'Andria M; Ferrara N; Salvatore D
    J Clin Med; 2022 Feb; 11(4):. PubMed ID: 35207295
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Patient perspectives following initiation of elexacaftor-tezacaftor-ivacaftor in people with cystic fibrosis and advanced lung disease.
    Martin C; Burnet E; Ronayette-Preira A; de Carli P; Martin J; Delmas L; Prieur B; Burgel PR
    Respir Med Res; 2021 Nov; 80():100829. PubMed ID: 34091202
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The French Compassionate Program of elexacaftor-tezacaftor-ivacaftor in people with cystic fibrosis with advanced lung disease and no F508del
    Burgel PR; Sermet-Gaudelus I; Durieu I; Kanaan R; Macey J; Grenet D; Porzio M; Coolen-Allou N; Chiron R; Marguet C; Douvry B; Dufeu N; Danner-Boucher I; Foucaud P; Lemonnier L; Girodon E; Da Silva J; Martin C;
    Eur Respir J; 2023 Feb; ():. PubMed ID: 36796836
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cystic fibrosis macrophage function and clinical outcomes after elexacaftor/tezacaftor/ivacaftor.
    Zhang S; Shrestha CL; Robledo-Avila F; Jaganathan D; Wisniewski BL; Brown N; Pham H; Carey K; Amer AO; Hall-Stoodley L; McCoy KS; Bai S; Partida-Sanchez S; Kopp BT
    Eur Respir J; 2023 Apr; 61(4):. PubMed ID: 36265882
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The rescue of F508del-CFTR by elexacaftor/tezacaftor/ivacaftor (Trikafta) in human airway epithelial cells is underestimated due to the presence of ivacaftor.
    Becq F; Mirval S; Carrez T; Lévêque M; Billet A; Coraux C; Sage E; Cantereau A
    Eur Respir J; 2022 Feb; 59(2):. PubMed ID: 34266939
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Elexacaftor-Tezacaftor-Ivacaftor for Cystic Fibrosis with a Single Phe508del Allele.
    Middleton PG; Mall MA; Dřevínek P; Lands LC; McKone EF; Polineni D; Ramsey BW; Taylor-Cousar JL; Tullis E; Vermeulen F; Marigowda G; McKee CM; Moskowitz SM; Nair N; Savage J; Simard C; Tian S; Waltz D; Xuan F; Rowe SM; Jain R;
    N Engl J Med; 2019 Nov; 381(19):1809-1819. PubMed ID: 31697873
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Olfactory dysfunction in cystic fibrosis: Impact of CFTR modulator therapy.
    Beswick DM; Humphries SM; Balkissoon CD; Strand M; Vladar EK; Ramakrishnan VR; Taylor-Cousar JL
    J Cyst Fibros; 2022 Mar; 21(2):e141-e147. PubMed ID: 34598881
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Eradication of Nontuberculous Mycobacteria in People with Cystic Fibrosis Treated with Elexacaftor/Tezacaftor/Ivacaftor: A Multicenter Cohort Study.
    Wiesel V; Aviram M; Mei-Zahav M; Dotan M; Prais D; Cohen-Cymberknoh M; Gur M; Bar-Yoseph R; Livnat G; Goldbart A; Hazan G; Hazan I; Golan-Tripto I
    J Cyst Fibros; 2024 Jan; 23(1):41-49. PubMed ID: 37173154
    [TBL] [Abstract][Full Text] [Related]  

  • 31. CFTR Modulators: Current Status and Evolving Knowledge.
    Regard L; Martin C; Da Silva J; Burgel PR
    Semin Respir Crit Care Med; 2023 Apr; 44(2):186-195. PubMed ID: 36535667
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Impact of elexacaftor-tezacaftor-ivacaftor on bacterial colonization and inflammatory responses in cystic fibrosis.
    Sheikh S; Britt RD; Ryan-Wenger NA; Khan AQ; Lewis BW; Gushue C; Ozuna H; Jaganathan D; McCoy K; Kopp BT
    Pediatr Pulmonol; 2023 Mar; 58(3):825-833. PubMed ID: 36444736
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Triple Therapy for Cystic Fibrosis
    Barry PJ; Mall MA; Álvarez A; Colombo C; de Winter-de Groot KM; Fajac I; McBennett KA; McKone EF; Ramsey BW; Sutharsan S; Taylor-Cousar JL; Tullis E; Ahluwalia N; Jun LS; Moskowitz SM; Prieto-Centurion V; Tian S; Waltz D; Xuan F; Zhang Y; Rowe SM; Polineni D;
    N Engl J Med; 2021 Aug; 385(9):815-825. PubMed ID: 34437784
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effects of Elexacaftor/Tezacaftor/Ivacaftor Therapy on Lung Clearance Index and Magnetic Resonance Imaging in Patients with Cystic Fibrosis and One or Two
    Graeber SY; Renz DM; Stahl M; Pallenberg ST; Sommerburg O; Naehrlich L; Berges J; Dohna M; Ringshausen FC; Doellinger F; Vitzthum C; Röhmel J; Allomba C; Hämmerling S; Barth S; Rückes-Nilges C; Wielpütz MO; Hansen G; Vogel-Claussen J; Tümmler B; Mall MA; Dittrich AM
    Am J Respir Crit Care Med; 2022 Aug; 206(3):311-320. PubMed ID: 35536314
    [No Abstract]   [Full Text] [Related]  

  • 35. Elexacaftor/tezacaftor/ivacaftor corrects monocyte microbicidal deficiency in cystic fibrosis.
    Cavinato L; Luly FR; Pastore V; Chiappetta D; Sangiorgi G; Ferrara E; Baiocchi P; Mandarello G; Cimino G; Del Porto P; Ascenzioni F
    Eur Respir J; 2023 Apr; 61(4):. PubMed ID: 36455959
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Physiologically Based Pharmacokinetic Modeling To Guide Management of Drug Interactions between Elexacaftor-Tezacaftor-Ivacaftor and Antibiotics for the Treatment of Nontuberculous Mycobacteria.
    Hong E; Almond LM; Chung PS; Rao AP; Beringer PM
    Antimicrob Agents Chemother; 2022 Nov; 66(11):e0110422. PubMed ID: 36286508
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clinical efficacy of elexacaftor-tezacaftor-ivacaftor in an adolescent with homozygous G85E cystic fibrosis.
    Stekolchik E; Saul D; Chidekel A
    Respir Med Case Rep; 2022; 40():101775. PubMed ID: 36411821
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Magnetic resonance imaging detects improvements of pulmonary and paranasal sinus abnormalities in response to elexacaftor/tezacaftor/ivacaftor therapy in adults with cystic fibrosis.
    Wucherpfennig L; Triphan SMF; Wege S; Kauczor HU; Heussel CP; Schmitt N; Wuennemann F; Mayer VL; Sommerburg O; Mall MA; Eichinger M; Wielpütz MO
    J Cyst Fibros; 2022 Nov; 21(6):1053-1060. PubMed ID: 35400600
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Suicide attempts in adolescents with cystic fibrosis on Elexacaftor/Tezacaftor/Ivacaftor therapy.
    Arslan M; Chalmers S; Rentfrow K; Olson JM; Dean V; Wylam ME; Demirel N
    J Cyst Fibros; 2023 May; 22(3):427-430. PubMed ID: 36759252
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Elexacaftor-Tezacaftor-Ivacaftor improves exercise capacity in adolescents with cystic fibrosis.
    Causer AJ; Shute JK; Cummings MH; Shepherd AI; Wallbanks SR; Pulsford RM; Bright V; Connett G; Saynor ZL
    Pediatr Pulmonol; 2022 Nov; 57(11):2652-2658. PubMed ID: 35851858
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.